Clinical Trial

CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer

Study acronym: CRYO-TOUCH
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Metastatic breast cancer remains an incurable disease for most patients. While surgical treatment of the primary breast tumor is commonly performed in localized breast cancer, its role in metastatic breast cancer remains controversial due to the lack of demonstrated survival benefit and the potential interruption of systemic anticancer therapies. Cryoablation is a minimally invasive outpatient procedure that destroys tumor tissue through controlled freezing. In localized breast cancer, cryoablation has shown promising results regarding local tumor control, safety, and patient quality of life. However, evidence regarding its use in metastatic breast cancer remains limited.The primary objective of this prospective single-center cohort study is to evaluate local tumor control 12 months after cryoablation of the primary breast tumor in patients with metastatic breast cancer.
Trial Details
NCT Number NCT07676344
Lead Sponsor Hospices Civils de Lyon
Conditions Metastatic Breast Cancer
Enrollment 42 participants
Start Date 2026-10-01
Primary Completion 2030-01-01 (estimated)
Study Completion 2030-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-30